Search

Your search keyword '"Schernthaner GH"' showing total 156 results

Search Constraints

Start Over You searched for: Author "Schernthaner GH" Remove constraint Author: "Schernthaner GH"
156 results on '"Schernthaner GH"'

Search Results

2. Beurteilung des klinischen Denkens von Studierenden am Ende des Klinisch-Praktischen Jahres: Das Portfolio als geeignetes Instrument? [Bericht über Entwicklungsprozess]

13. Research update for articles published in EJCI in 2011

14. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

16. Urinary vanin-1 as a novel biomarker for survival in peripheral artery disease.

17. A RAND/UCLA-Modified VAS Study on Telemedicine, Telehealth, and Virtual Care in Daily Clinical Practice of Vascular Medicine.

18. Serum Trefoil Factor-3 Predicts Survival in Peripheral Artery Disease.

19. Peripheral Arterial Disease: An Underestimated Aspect of Menopause-related Cardiovascular Disease.

20. Thyroid Disorders and Peripheral Arterial Disease.

21. Hyperparathyroidism and Peripheral Arterial Disease.

22. Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess.

23. Growth Hormone, Atherosclerosis and Peripheral Arterial Disease: Exploring the Spectrum from Acromegaly to Growth Hormone Deficiency.

24. Involvement of APOE in Incidence of Revascularization in Patients Affected by Peripheral Arterial Disease: A Prospective Study from Southern Italy.

25. The importance of socio-economic determinants of health in the care of patients with peripheral artery disease: A narrative review from VAS.

26. NT-proBNP as a surrogate for unknown heart failure and its predictive power for peripheral artery disease outcome and phenotype.

28. Secondary calciprotein particle size is associated with patient mortality in peripheral artery disease.

29. The Effect of Menopause and Menopausal Hormone Therapy on the Risk of Peripheral Artery Disease.

30. Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management.

31. [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)].

32. Testosterone and Peripheral Arterial Disease.

33. Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization.

34. High-Density Lipoprotein Particle Subclasses in Statin-Treated Patients with Peripheral Artery Disease Predict Long-Term Survival.

35. UEMS Training Requirements for Angiology/Vascular Medicine: European Standards of Postgraduate Medical Specialist Training (2022 Updated Version).

36. Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease.

37. Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?

38. Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality.

40. Angiogenin-A Proposed Biomarker for Cardiovascular Disease-Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease.

42. Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery.

43. Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease.

44. Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.

45. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality.

46. GlycA for long-term outcome in T2DM secondary prevention.

50. Predictive power of novel and established obesity indices for outcome in PAD during a five-year follow-up.

Catalog

Books, media, physical & digital resources